|
1
|
Francis H, Alpini G and DeMorrow S: Recent
advances in the regulation of cholangiocarcinoma growth. Am J
Physiol Gastrointest Liver Physiol. 299:G1–G9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gatto M, Bragazzi MC, Semeraro R, Napoli
C, Gentile R, Torrice A, Gaudio E and Alvaro D: Cholangiocarcinoma:
Update and future perspectives. Dig Liver Dis. 42:253–260. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mavros MN, Economopoulos KP, Alexiou VG
and Pawlik TM: Treatment and prognosis for patients with
intrahepatic cholangiocarcinoma: Systematic review and
meta-analysis. JAMA Surg. Apr 9–2014.Epub ahead of print.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou H, Wang H, Zhou D, Wang H, Wang Q,
Zou S, Tu Q, Wu M and Hu H: Hepatitis B virus-associated
intrahepatic cholangiocarcinoma and hepatocellular carcinoma may
hold common disease process for carcinogenesis. Eur J Cancer.
46:1056–1061. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sulpice L, Rayar M, Boucher E, Pele F,
Pracht M, Meunier B and Boudjema K: Intrahepatic
cholangiocarcinoma: Impact of genetic hemochromatosis on outcome
and overall survival after surgical resection. J Surg Res.
180:56–61. 2013. View Article : Google Scholar
|
|
8
|
Dodson RM, Weiss MJ, Cosgrove D, Herman
JM, Kamel I, Anders R, Geschwind JF and Pawlik TM: Intrahepatic
cholangiocarcinoma: Management options and emerging therapies. J Am
Coll Surg. 217:736–750.e4. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olzmann JA, Brown K, Wilkinson KD, Rees
HD, Huai Q, Ke H, Levey AI, Li L and Chin LS: Familial Parkinson's
disease-associated L166P mutation disrupts DJ-1 protein folding and
function. J Biol Chem. 279:8506–8515. 2004. View Article : Google Scholar
|
|
10
|
Maita C, Maita H, Iguchi-Ariga SM and
Ariga H: Monomer DJ-1 and its N-terminal sequence are necessary for
mitochondrial localization of DJ-1 mutants. PLoS One. 8:e540872013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah SP, Lonial S and Boise LH: When
cancer fights back: Multiple myeloma, proteasome inhibition, and
the heat-shock response. Mol Cancer Res. 13:1163–1173. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoo HM, Park JH, Jeon YJ and Chung CH:
Ubiquitin-fold modifier 1 acts as a positive regulator of breast
cancer. Front Endocrinol (Lausanne). 6:362015.
|
|
13
|
Wan J, Zhan J, Li S, Ma J, Xu W, Liu C,
Xue X, Xie Y, Fang W, Chin YE, et al: PCAF-primed EZH2 acetylation
regulates its stability and promotes lung adenocarcinoma
progression. Nucleic Acids Res. 43:3591–3604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oram SW, Ai J, Pagani GM, Hitchens MR,
Stern JA, Eggener S, Pins M, Xiao W, Cai X, Haleem R, et al:
Expression and function of the human androgen-responsive gene ADI1
in prostate cancer. Neoplasia. 9:643–651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Ding N, Li Y, Cheng H, Wang D,
Yang Q, Deng Y, Yang Y, Li Y, Ruan X, et al: Insulin-like growth
factor binding protein 5 (IGFBP5) functions as a tumor suppressor
in human melanoma cells. Oncotarget. 6:20636–20649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ling J, Jiang L, Zhang C, Dai J, Wu Q and
Tan J: Upregulation of miR-197 inhibits cell proliferation by
directly targeting IGFBP5 in human uterine leiomyoma cells. In
Vitro Cell Dev Biol Anim. 51:835–842. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Güllü G, Peker I, Haholu A, Eren F,
Küçükodaci Z, Güleç B, Baloglu H, Erzik C, Özer A and Akkiprik M:
Clinical significance of miR-140-5p and miR-193b expression in
patients with breast cancer and relationship to IGFBP5. Genet Mol
Biol. 38:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kavalieris L, O'Sullivan PJ, Suttie JM,
Pownall BK, Gilling PJ, Chemasle C and Darling DG: A segregation
index combining phenotypic (clinical characteristics) and genotypic
(gene expression) biomarkers from a urine sample to triage out
patients presenting with hematuria who have a low probability of
urothelial carcinoma. BMC Urol. 15:232015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang Y, Shen P, Chen X, Chen Z, Zhao T,
Chen N, Gong J, Nie L, Xu M, Li X, et al: Transcriptional
regulation of BNIP3 by Sp3 in prostate cancer. Prostate.
75:1556–1567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang K, Wang W, Jin X, Wang Z, Ji Z and
Meng G: Silibinin, a natural flavonoid, induces autophagy via
ROS-dependent mitochondrial dysfunction and loss of ATP involving
BNIP3 in human MCF7 breast cancer cells. Oncol Rep. 33:2711–2718.
2015.PubMed/NCBI
|
|
21
|
Cherigo L, Lopez D and Martinez-Luis S:
Marine natura products as breast cancer resistance protein
inhibitors. Mar Drugs. 13:2010–2029. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Van Bael K, Jansen Y, Seremet T, Engels B,
Delvaux G and Neyns B: A case report of long-term survival
following hepatic arterial infusion of L-folinic acid modulated
5-fluorouracil combined with intravenous irinotecan and cetuximab
followed by hepatectomy in a patient with initially unresectable
colorectal liver metastases. Case Rep Oncol Med.
2015:4720372015.
|
|
23
|
Hayashi H, Beppu T, Sakamoto Y, Miyamoto
Y, Yokoyama N, Higashi T, Nitta H, Hashimoto D, Chikamoto A and
Baba H: Prognostic value of Ki-67 expression in conversion therapy
for colorectal liver-limited metastases. Am J Cancer Res.
5:1225–1233. 2015.PubMed/NCBI
|
